Imatinib is a small molecule inhibitor of the constitutively active fusion BCR-ABL kinase which is present in more than 90% of chronic myeloid leukaemia (CML) cases and 30% of B-cell acute lymphoblastic leukaemia cases [64]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.